VERV
Verve Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website vervetx.com
- Employees(FY) 204
- ISIN US92539P1012
Performance
-1.6%
1W
-27.7%
1M
-46.25%
3M
-58.88%
6M
-55.81%
YTD
-62.0%
1Y
Profile
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: VERV
Overview
VERV is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has shown significant growth in its financial metrics over the past three years, with a market capitalization of $1.028 billion. In this report, we will analyze VERV's financial health, ea...
Technical Analysis of VERV 2024-05-03
Overview:
In analyzing the technical indicators for VERV over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-07 07:00
- 2024-05-06 19:00
- 2024-05-03 16:01
- 2024-05-03 04:01
- 2024-04-25 09:00
- 2024-04-18 22:30
- 2024-04-06 09:50
- 2024-04-04 13:21
- 2024-04-03 13:40
- 2024-04-03 01:40
- 2024-04-02 16:04
Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects(Investor's Business Daily)
- 2024-04-02 07:35
- 2024-04-02 07:28
- 2024-04-02 07:00
- 2024-04-02 07:00
Verve Therapeutics Announces Updates on its PCSK9 Program(GlobeNewswire)
- 2024-04-02 03:03
Verve pauses base editing study after treatment side effect(BioPharma Dive)
- 2024-04-01 22:36
- 2024-04-01 21:01
- 2024-04-01 19:00
Verve Therapeutics Announces Updates on its PCSK9 Program(Globenewswire)
- 2024-03-28 16:51
- 2024-03-28 04:51
- 2024-03-21 16:19
3 Stocks That Could Be the Next Big Thing in Gene Editing(InvestorPlace)
- 2024-03-01 16:01
- 2024-03-01 03:01
- 2024-02-29 06:12
- 2024-02-28 06:00
Verve Therapeutics Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-02-27 19:02
- 2024-02-27 08:03
Verve Therapeutics: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-02-27 07:30
- 2024-02-26 18:30
Page 1 of 5
previousnext